Supercharged immune cells take on Drug-Resistant infections
NCT ID NCT03159364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether specially grown immune cells, called pathogen-specific cytotoxic T lymphocytes (CTLs), can safely and effectively treat stubborn infections like EBV, CMV, and adenovirus in people with weakened immune systems, such as stem cell or organ transplant recipients. Participants receive one or more infusions of these cells, which are designed to target and kill infected cells. The study aims to see if this approach can reduce viral levels and control infections when standard drugs have failed or cannot be used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pathogen-specific cytotoxic T lymphocytes (CTLs)
What this could lead to
If it works, this approach could offer a new way to control serious infections in people with weak immune systems, especially when standard drugs fail.
What could go wrong
This is an early-phase trial, so the treatment may not work or could cause side effects like infusion reactions or graft-versus-host-like symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••